APA (7th ed.) Citation

MJ, C., D, T., LF, E., PD, A., Z, C., RB, T., . . . NA, L. (2023). Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis. Dermatology and therapy, 13(11), 2697. https://doi.org/10.1007/s13555-023-01016-9

Chicago Style (17th ed.) Citation

MJ, Cork, et al. "Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis." Dermatology and Therapy 13, no. 11 (2023): 2697. https://doi.org/10.1007/s13555-023-01016-9.

MLA (9th ed.) Citation

MJ, Cork, et al. "Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis." Dermatology and Therapy, vol. 13, no. 11, 2023, p. 2697, https://doi.org/10.1007/s13555-023-01016-9.